Drug recall · August 17, 2022
Lorazepam Injection recall
Why: Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Lorazepam Injection, USP, 4mg/mL, 1 mL vial, 25 vial per carton, Rx Only, Novaplus, Manufactured by Hikma Berkeley Heights, NJ 07922. Carton NDC# NDC# 0641-6045-25, Vial NDC# 0641-6045-01
- Lots / codes
Lot # 070096, exp. date 07/2023
- Quantity
- 82,700 vials
- Company
- Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ
- Distribution
- Nationwide in the USA
- Initiated
- July 11, 2022 · Voluntary: Firm initiated
- Classified
- August 5, 2022
- Reported
- August 17, 2022
- Ended
- September 14, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Lorazepam
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.